Vir, Alnylam plan human trials by year-end for potential COVID-19 therapy

(Reuters) – Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc plan to begin human testing of their COVID-19 drug candidate by the end of the year, as drugmakers across the globe scramble to find therapies for the highly-infectious virus. The are currently ... More »